雷帕霉素对急性髓系白血病细胞系HL-60和HL-60/VCR生长的抑制作用

为了探讨mTOR抑制剂雷帕霉素对急性髓系白血病（acute myeloid leukemia;AML）细胞的增殖和药物敏感性的影响。以AML细胞株HL-60和多药耐药HL-60/VCR细胞系为研究对象,采用MTT法测定生长曲线和流式细胞术检测细胞周期;Western blot检测P糖蛋白（P-glycoprotein,Pgp）的表达。结果显示：与空白对照组细胞比较,雷帕霉素能抑制HL-60和HL-60/VCR细胞生长增殖（p〈0.05）,且随着浓度升高,增殖抑制率逐渐增高,24-72小时的细胞增殖抑制率随着时间的延长而有所增高（p〈0.05）,同时可阻滞细胞从G1期到S期的细胞周期转换。雷帕霉素抑制HL-60/VCR细胞的Pgp蛋白的表达。与柔红霉素单独应用相比,雷帕霉素50nmol/L、100nmol/L与柔红霉素联合应用使HL-60和HL-60/VCR细胞增殖抑制率明显增高（p〈0.05）,尤其是当先加雷帕霉素,而24小时后再加柔红霉素时。结论：mTOR抑制剂雷帕霉素对HL-60和多药耐药的HL-60/VCR细胞的生长均有抑制作用,除伴G0/G1期阻滞外,还增加细胞对柔红霉素的敏感性,这为临床难治性AML治疗提供新的治疗手段。

Effect of Rapamycin on Proliferation of Acute Myeloid Leukemia Cell Lines HL-60 and HL-60/VCR

In order to investigate the effect of rapamycin on the proliferation of human acute myeloid leukemia （AML） cells,the sensitive cells HL-60 and multidrug-resistant HL-60/VCR cells were chosen as research objects. The proliferation of cells was detected by growth curve method. The flow cytometer was used to analyze cell cycle. The expression of P-glycoprotein （Pgp） was determined by Western blot. The results demonstrated that there was a significant difference of cell growth inhibition rate between control group and rapamycin group （p0.05）. The cell growth inhibition rate was dose- and time- dependent（p0.05）. Flow cytometry detection showed that the cell percentage of G1 phase in rapamycin group was higher than that in group without rapamycin,and that of S phase was lower. The cell growth inhibition rate in 50 nmol/L and 100 nmol/L rapamycin plus daunorubicin （DNR） group was more than that in DNR alone group（p0.05）,especially when DNR was added at 24 hours interval after RAP. The expression of Pgp of HL-60/VCR cells was inhibited by rapamycin. It is concluded that the rapamycin can inhibit the proliferation of sensitive HL-60 and multidrug resistant HL-60/VCR cells. It can also increase sensitivity of HL-60 and HL-60/VCR cells to DNR,which provides new strategy for the therapy of refractory AML.